Sientra Inc. (SIEN) Upgraded by Zacks Investment Research to Hold
Sientra Inc. (NASDAQ:SIEN) was upgraded by Zacks Investment Research from a “sell” rating to a “hold” rating in a research note issued on Wednesday.
According to Zacks, “Sientra, Inc. is a medical aesthetics company. The Company offers plastic surgery implantable devices for cosmetic and reconstructive surgery, including Breast Implants, Tissue Expanders, Body Contouring, Implants and Specialty Products. Sentra’s primary products are silicone gel breast implants for use in breast augmentation and breast reconstruction procedures. It also offers a range of other aesthetic and specialty products. Sientra, Inc. is headquartered in Santa Barbara, California. “
Separately, William Blair restated a “market perform” rating on shares of Sientra in a report on Wednesday, August 10th.
Sientra (NASDAQ:SIEN) opened at 9.00 on Wednesday. The firm’s 50-day moving average is $8.46 and its 200-day moving average is $7.41. The firm’s market capitalization is $163.21 million. Sientra has a 12 month low of $2.78 and a 12 month high of $10.45.
Sientra (NASDAQ:SIEN) last issued its quarterly earnings results on Tuesday, August 9th. The company reported ($0.56) earnings per share for the quarter, missing the Zacks’ consensus estimate of ($0.51) by $0.05. Sientra had a negative net margin of 297.09% and a negative return on equity of 36.16%. The business earned $6.20 million during the quarter, compared to analyst estimates of $4.80 million. On average, equities research analysts expect that Sientra will post ($2.31) EPS for the current year.
Hedge funds have recently bought and sold shares of the company. First New York Securities LLC NY increased its stake in Sientra by 411.4% in the second quarter. First New York Securities LLC NY now owns 15,343 shares of the company’s stock valued at $101,000 after buying an additional 12,343 shares during the last quarter. State Street Corp increased its stake in Sientra by 23.9% in the first quarter. State Street Corp now owns 82,717 shares of the company’s stock valued at $563,000 after buying an additional 15,954 shares during the last quarter. Geode Capital Management LLC increased its stake in Sientra by 67.5% in the first quarter. Geode Capital Management LLC now owns 71,919 shares of the company’s stock valued at $491,000 after buying an additional 28,980 shares during the last quarter. Paloma Partners Management Co bought a new stake in Sientra during the second quarter valued at about $198,000. Finally, Cannell Capital LLC increased its stake in Sientra by 95.2% in the second quarter. Cannell Capital LLC now owns 855,997 shares of the company’s stock valued at $5,632,000 after buying an additional 417,364 shares during the last quarter. Hedge funds and other institutional investors own 68.85% of the company’s stock.
Sientra Company Profile
Sientra, Inc is a medical aesthetics company. The Company’s primary products are silicone gel breast implants for use in breast augmentation and breast reconstruction procedures, which it offers in over 190 variations of shapes, sizes and textures. The Company sells its breast implants and breast tissue expanders, or breast products to plastic surgeons.
Receive News & Stock Ratings for Sientra Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Sientra Inc. and related stocks with our FREE daily email newsletter.